CR20220160A - Derivados de piridazin-3(2h)-ona fusionados con azol - Google Patents

Derivados de piridazin-3(2h)-ona fusionados con azol

Info

Publication number
CR20220160A
CR20220160A CR20220160A CR20220160A CR20220160A CR 20220160 A CR20220160 A CR 20220160A CR 20220160 A CR20220160 A CR 20220160A CR 20220160 A CR20220160 A CR 20220160A CR 20220160 A CR20220160 A CR 20220160A
Authority
CR
Costa Rica
Prior art keywords
pyridazin
azole
fused
derivatives
gpr139
Prior art date
Application number
CR20220160A
Other languages
English (en)
Spanish (es)
Inventor
Sean Murphy
Melinda Davis
Scott Olsen
Holly Reichard
Holger Monenschein
Natasha O'rourke
Betty Lam
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CR20220160A publication Critical patent/CR20220160A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR20220160A 2019-09-16 2020-09-15 Derivados de piridazin-3(2h)-ona fusionados con azol CR20220160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962901052P 2019-09-16 2019-09-16
PCT/US2020/050823 WO2021055326A1 (fr) 2019-09-16 2020-09-15 Dérivés de pyridazin-3(2h)-one fusionnés par un azole

Publications (1)

Publication Number Publication Date
CR20220160A true CR20220160A (es) 2022-06-16

Family

ID=72670806

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220160A CR20220160A (es) 2019-09-16 2020-09-15 Derivados de piridazin-3(2h)-ona fusionados con azol

Country Status (19)

Country Link
US (1) US20230028114A1 (fr)
EP (1) EP4031552A1 (fr)
JP (1) JP2022548602A (fr)
KR (1) KR20220063228A (fr)
CN (1) CN114728975A (fr)
AR (1) AR119971A1 (fr)
AU (1) AU2020348675A1 (fr)
BR (1) BR112022004819A2 (fr)
CA (1) CA3150508A1 (fr)
CO (1) CO2022004684A2 (fr)
CR (1) CR20220160A (fr)
DO (1) DOP2022000057A (fr)
EC (1) ECSP22020159A (fr)
IL (1) IL291181A (fr)
JO (1) JOP20220063A1 (fr)
MX (1) MX2022003177A (fr)
PE (1) PE20221341A1 (fr)
TW (1) TW202124386A (fr)
WO (1) WO2021055326A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114149371B (zh) * 2021-11-26 2023-08-22 首都医科大学 四取代吡唑类化合物及其应用
WO2023165262A1 (fr) * 2022-03-01 2023-09-07 上海科技大学 Composé hétérocyclique contenant un thiéno-azote, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
WO2023165263A1 (fr) * 2022-03-01 2023-09-07 上海科技大学 Composé de pyrrolotriazinone, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
WO2024121046A1 (fr) * 2022-12-05 2024-06-13 Angelini Pharma S.P.A. Composés amides utilisés en tant qu'activateurs des canaux potassiques kv7.2/kv7.3 utiles dans le traitement de troubles du snc et du snp
CN116063179A (zh) * 2023-02-20 2023-05-05 南京杰运医药科技有限公司 一种4-甲氧基乙酰乙酸甲酯的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20140336216A1 (en) 2013-03-14 2014-11-13 Janssen Pharmaceutica Nv Physiological ligands for gpr139
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
BR112022004819A2 (pt) 2022-06-07
AU2020348675A1 (en) 2022-04-14
ECSP22020159A (es) 2022-05-31
EP4031552A1 (fr) 2022-07-27
KR20220063228A (ko) 2022-05-17
AR119971A1 (es) 2022-01-26
US20230028114A1 (en) 2023-01-26
CA3150508A1 (fr) 2021-03-25
CN114728975A (zh) 2022-07-08
PE20221341A1 (es) 2022-09-13
WO2021055326A1 (fr) 2021-03-25
JOP20220063A1 (ar) 2023-01-30
MX2022003177A (es) 2022-04-06
DOP2022000057A (es) 2022-06-30
CO2022004684A2 (es) 2022-07-08
IL291181A (en) 2022-05-01
JP2022548602A (ja) 2022-11-21
TW202124386A (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2020007265A (es) Derivados de rapamicina.
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
MX2020009062A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos.
MX2021010888A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis.
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
PH12021550872A1 (en) Therapeutic compounds
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2018011283A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer.
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
CR20210544A (es) DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2
PH12017501736A1 (en) Indole derivatives